Systemic Immune-Inflammation Index as a Prognostic Marker in Mycosis Fungoides.
A simple blood count calculation accurately distinguishes early from advanced mycosis fungoides, offering affordable disease staging for this rare cancer.
In 126 mycosis fungoides patients, the systemic immune-inflammation index (SII) demonstrated high diagnostic accuracy for distinguishing early from advanced disease stages (AUC 0.891), outperforming NLR and LMR. As an easily calculated CBC-derived marker, SII could provide cost-effective prognostic stratification for this rare cutaneous T-cell lymphoma.
What the study was
- Study design
- Retrospective cohort study
- Population
- Patients with mycosis fungoides at a tertiary center (n=126)
- Sample size
- 126
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Annals of Clinical and Laboratory Science
Why it surfaced
Retrospective validation of SII as prognostic tool in mycosis fungoides (n=126). Relevant to both hematologic malignancy and CBC-based diagnostics topics. The CBC-derivability and high AUC make it near-term implementable. Score limited by single-center retrospective design and small n.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.